Litigation Details for ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)
✉ Email this page to a colleague
ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-10-30 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | William H. Walls |
| Jury Demand | Both | Referred To | |
| Patents | 9,770,453; 9,907,801; 9,907,802 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ALLERGAN SALES, LLC v. SANDOZ, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for ALLERGAN SALES, LLC v. SANDOZ, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-08-29 | 195 | drug Combigan® infringes U.S. Patent Nos. 9,770,453 (“the ’453 patent”), 9,907,801 (“the ’801 pa- tent… of the patent claim. “It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the…tent”), and 9,907,802 (“the ’802 patent”) (collectively, “the Patents-in-Suit”) owned by Allergan. The …Because the Patents-in-Suit share a common spec- ification, we cite to only the ’453 patent for ease of… of the ’453 patent recites both a representative efficacy “wherein” clause, ’453 patent col. 9 l. 20– | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
